Furthermore, ARID2 and NTRK1 alterations could serve as predictive markers, in the context of other clinical and pathologic findings, as clinicians make management decisions related to CPIs in patients with MCC. This evidence concerns the gene NTRK1 and Merkel cell skin cancer.